As of August 29, 2026, Prelude Therapeutics's top three insider holders are Advisors Llc Orbimed (Director, 10.12Mn shares), Krishna Vaddi (Ceo, 2.00Mn shares), Krishna Vaddi (Ceo, 2.00Mn shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Advisors Llc Orbimed | Director, TenPercentOwner | 0 | 10,119,756 | 10,119,756 | 49.3% | 24 May, 2023 |
| 2 | Capital Management, L.P. Ra | TenPercentOwner | 0 | 6,475,882 | 6,475,882 | 31.5% | 28 Apr, 2026 |
| 3 | Krishna Vaddi | Ceo | 1,999,296 | 0 | 1,999,296 | 9.7% | 27 Mar, 2025 |
| 4 | David P Bonita | Director, TenPercentOwner | 0 | 1,126,126 | 1,126,126 | 5.5% | 23 Apr, 2026 |
| 5 | Andrew Combs | Chief Chemistry Officer | 480,123 | 0 | 480,123 | 2.3% | 27 Mar, 2025 |
| 6 | Peggy Scherle | Chief Scientific Officer | 172,920 | 0 | 172,920 | 0.8% | 30 Aug, 2021 |
| 7 | Jane Huang | President, Cmo | 86,917 | 0 | 86,917 | 0.4% | 07 Oct, 2025 |
| 8 | Laurent Chardonnet | Chief Financial Officer | 42,165 | 0 | 42,165 | 0.2% | 25 May, 2023 |
| 9 | Bryant David Lim | Clo, Interim Cfo, Corp Sec. | 27,400 | 0 | 27,400 | 0.1% | 20 Dec, 2024 |
| 10 | Deborah Morosini | Evp, Chief Of Clinical Affairs | 444 | 0 | 444 | 0.0% | 17 Dec, 2021 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 09 Jun, 2026 | Victor Sandor | Director | Acquired A | 38,000 | $0.00 | $0 | 38,000 | Direct |
| 09 Jun, 2026 | David P Bonita | Director, TenPercentOwner | Acquired A | 38,000 | $0.00 | $0 | 38,000 | Direct |
| 09 Jun, 2026 | Martin Babler | Director | Acquired A | 38,000 | $0.00 | $0 | 38,000 | Direct |
| 09 Jun, 2026 | Katina Dorton | Director | Acquired A | 38,000 | $0.00 | $0 | 38,000 | Direct |
| 01 May, 2026 | Charles Q Morris | Chief Medical Officer | Acquired A | 450,000 | $4.70 | $2.12Mn | 450,000 | Direct |
| 27 Apr, 2026 | Capital Management, L.P. Ra | TenPercentOwner | Disposed J | 1,407,000 | — | — | 6,475,882 | Indirect |
| 27 Apr, 2026 | Capital Management, L.P. Ra | TenPercentOwner | Acquired J | 1,407,000 | — | — | 1,407,000 | Indirect |
| 21 Apr, 2026 | David P Bonita | Director, TenPercentOwner | Acquired P | 1,689,189 | $4.44 | $7.50Mn | 11,808,945 | Indirect |
| 21 Apr, 2026 | David P Bonita | Director, TenPercentOwner | Acquired P | 1,126,126 | $4.44 | $5.00Mn | 1,126,126 | Indirect |
| 04 Feb, 2026 | Peggy Scherle | Chief Scientific Officer | Acquired A | 230,000 | $0.00 | $0 | 230,000 | Direct |
| 04 Feb, 2026 | Peggy Scherle | Chief Scientific Officer | Acquired A | 230,000 | $0.00 | $0 | 230,000 | Direct |
| 04 Feb, 2026 | Peggy Scherle | Chief Scientific Officer | Acquired A | 230,000 | $0.00 | $0 | 230,000 | Direct |
| 04 Feb, 2026 | Krishna Vaddi | Ceo | Acquired A | 837,000 | $0.00 | $0 | 837,000 | Direct |
| 04 Feb, 2026 | Krishna Vaddi | Ceo | Acquired A | 837,000 | $0.00 | $0 | 837,000 | Direct |
| 04 Feb, 2026 | Krishna Vaddi | Ceo | Acquired A | 837,000 | $0.00 | $0 | 837,000 | Direct |
| 04 Feb, 2026 | Peggy Scherle | Chief Scientific Officer | Acquired A | 230,000 | $0.00 | $0 | 230,000 | Direct |
| 04 Feb, 2026 | Bryant David Lim | Clo, Cfo, Corp Sec. | Acquired A | 275,000 | $0.00 | $0 | 275,000 | Direct |
| 04 Feb, 2026 | Krishna Vaddi | Ceo | Acquired A | 837,000 | $0.00 | $0 | 837,000 | Direct |
| 04 Feb, 2026 | Krishna Vaddi | Ceo | Acquired A | 837,000 | $0.00 | $0 | 837,000 | Direct |
| 04 Feb, 2026 | Peggy Scherle | Chief Scientific Officer | Acquired A | 230,000 | $0.00 | $0 | 230,000 | Direct |